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Crohn's disease (CD) and ulcerative colitis (UC) are inflammatory bowel diseases (IBD) characterized by chronic relapsing and remitting courses requiring ongoing adjustments in therapy and constant interactions with the healthcare system. The prevalence of IBD is estimated to be over 3 million persons in the US and Europe, and the incidence of IBD is increasing worldwide among developed and developing countries. 1 IBD ranks as one of the top 5 most expensive GI conditions, with direct costs estimated to exceed $6 billion dollars per year in the US alone. 2, 3 IBD patients also have significant indirect costs through social and psychological impacts from their chronic disease state, which negatively affect their overall quality of life, and create substantial burdens to caregivers and communities. 4 Similar to most chronic diseases, 25%-30% of IBD patients account for over 80% of total IBD healthcare burden, [5] [6] [7] and psycho-socioeconomic, disease, and treatment determinants of health are the primary drivers for variability in care, expenditure, and outcomes. 3 An important and emerging concept within the field of IBD is population health management (PHM) -coordination of care at a macro level to improve outcomes and effectively manage clinical and financial risks for a defined group of individuals. 8 Although conceptually important, the operationalization of PHM for IBD will require a multi-step process across various healthcare platform domains. In this review we discuss the key components to a successful PHM strategy for IBD.
POPULATION HEALTH MANAGEMENT
The core principles of PHM are to shift from volume to value by improving the quality of care delivered, improving population health outcomes, and reducing healthcare costs (a triple aim). 8, 9 This triple aim can be broken down into actionable components (adapted from National Quality Strategy for Improvement in Health Care) 10 :
1. Make care safer by reducing harm caused in the delivery of care 2. Ensure providers, patients, families, and communities are engaged as partners 3. Promote effective communication and coordination of care 4. Promote the most effective, risk-stratified, prevention and treatment practices To achieve these aims, healthcare systems will need to first identify high-risk populations, drivers of cost, and variability in care within their specific populations (Figure 1 ).
IDENTIFYING HIGH RISK POPULATIONS, VARIATIONS IN CARE, AND FACTORS THAT AFFECT COST
The most important component of an effective PHM strategy is the application of an operational improvement methodology, such as Lean Six Sigma, which includes collaborative efforts to reduce error, remove waste, and improve performance, by ensuring consistent delivery of desired results, with a focus on patient experience. The first step in this process is to define the population, deficits and care, and drivers of cost.
Patients with IBD can be categorized as well patients who require minimal health care
interactions, so the focus should be on maintaining their health (primary prevention); patients at Patients at risk can be identified through an evaluation of known principal determinants, drivers, and predictors of IBD health and healthcare expenditure (Figure 2) . [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] The greatest degree of variability in care for these patients occurs in: diagnosis and management of acute disease flares (delay in initial IBD diagnosis or diagnosis of an acute disease flare due to lack of access or lack of guideline-congruent care), prevention of complications (inappropriate use of ineffective therapy without adequate risk stratification and prognostication through prediction modeling, delay in use of effective therapy resulting in loss of window of opportunity, fragmentation of healthcare resulting in inadequate communication, interruption of therapy), and minimization of treatment-related risks (inadequate understanding of differential risks with therapies promoting inappropriate use). These determinants could serve as triggers for PHM systems to identify subpopulations and healthcare interactions at greatest need for optimized coordinated care.
CHRONIC CARE MODELS (CCMs) TO IMPROVE CONSISTENCY OF DELIVERY
Once identified, at-risk populations would benefit from multi-component CCMs designed to shift from acute, episodic, and reactive encounters, to proactive, planned, and individualized longterm care. The goals of a CCM are to meet the needs of patients and providers, while M A N U S C R I P T
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enhancing the ability to co-produce high quality evidence-based care. 30, 31 These goals can be achieved through the 6 related components of a CCM (see Table 1 ). CCMs have been shown to improve the overall quality of care delivered in other chronic health conditions (i.e. diabetes, congestive heart failure, asthma, and chronic obstructive pulmonary diseases) by improving patient satisfaction and function, adherence to guideline recommended care, and most importantly, clinical outcomes through reductions in unplanned healthcare utilization, hospitalizations, disease related complications, and mortality. 32 Below are examples of IBDfocused PHM strategies that are active: . 36 This specialty-based intensive medical home also provides insight into cost normalization, 36 and the ability to implement a shared savings model which is central to the development of IBD specific Accountable Care Organizations. caring for approximately 20,000 adults with IBD. 38 Co-production models offer distinct advantages over IBD specialty homes, particularly in resource-limited countries, as the level of engagement and infrastructure can be tailored to local needs and resource availability.
The visualization of at-risk patients and physician or system-level performance metrics can be personalized based on drivers of cost to that specific region or country or local guideline recommendations and availability of alternative therapies (i.e. biosimilars). IBD Qorus provides a framework for this model in adults, but a similar IBD-focused pediatric learning health system, ImproveCareNow, has been shown to increase patient engagement and follow up and improve outcomes. These examples provide a framework for opportunities to implement CCMs. The most effective delivery of healthcare will likely be through a combination of CCM features that target areas of greatest variability or needs specific to each healthcare system and population. This is of particular importance on the international level where significant variations exist in healthcare system models, payors, and costs.
MEASURING PERFORMANCE AND REDEFINING METRICS
Important components of an effective PHM strategy are performance measurement, tracking, and analysis. To assist providers in delivering high-quality, high-value care, the Institute of Medicine developed quality measures and metrics that can be used for reimbursement decisions in IBD (Physician Quality Reporting System). Although these indicators are important, and should be addressed by all PHM strategies, they do not capture or provide recommendations to achieve uniformity or consistency with healthcare delivery or treatment outcomes. To further expand on these measures, the AGA and the Crohn's and Colitis
Foundation have developed IBD-specific quality indicators that address various facets of IBD care, from disease activity assessment (documenting disease type, location, and activity), to primary (smoking cessation, vaccinations, infection screening, cancer surveillance), secondary (venous thromboembolism prophylaxis, minimization of corticosteroid use, immunosuppressive use, bone loss screening), and tertiary (timing of surgical referral, quality of life and disability assessment) preventive measures. 25 As defined, these measures risk spending considerable effort focusing on what is measurable, rather than measuring what makes a difference in outcomes. Remaining limitations include an absence of more objective performance metrics that are known to affect treatment and disease outcomes, and our inability to accurate capture and share performance metrics among populations.
Potentially important measures that are not being adequately captured include:
1. Assessing disease activity and achieving mucosal healing: AGA and Crohn's and
Colitis Foundation IBD quality measures include metrics on the assessment of clinical M A N U S C R I P T
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8 disease activity and severity, and on the proportion of patients who have achieved steroid-free clinical remission for >12 months. These metrics carry inherent limitations because they do not provide ongoing information to providers to help improve the probability of achieving key endpoints known to improve IBD health outcomes. 46, 47 Mucosal healing is an important treatment target given the association between achieving mucosal healing and reducing the risk of disease related complications (hospitalization, cancer, surgery). Treatment strategies have now shifted towards achieving mucosal healing through treat to target algorithms. [47] [48] [49] A retrospective review associated frequent assessment of endoscopic disease activity (within 26 weeks of treatment initiation or adjustment) with increased probability of achieving mucosal healing (odds ratio, 2.35). 50 A cluster-randomized trial (Enhanced Algorithm for Crohn's Treatment Incorporating Early Combination Therapy, REACT2) is nearing completion; it will definitively evaluate the importance of this endpoint and the effects of frequent endoscopic assessments on long-term outcomes (hospitalization, surgery, disease related complications). reduction in cost for a subset of patients with high drug concentrations. 52 Analogous to the quality metrics of simply measuring microalbuminuria or hemoglobin A1c for diabetes, PHM systems can consider that if these assessments occur in IBD (i.e. checking for mucosal disease activity through endoscopy or biomarkers, and measuring drug concentrations), then providers will adjust therapies until endpoints or therapeutic targets are achieved (i.e. mucosal healing or biomarker normalization, target drug concentrations). 48 These are two potential metrics for consideration in PHM, and evidence-based metrics with prospective studies supporting their value will need to be identified.
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An important limitation to tracking any performance measure is the ability to accurately validate and share data. Of the 21 measures included in the AGA and the Crohn's and Colitis Foundation recommendations, 11 could not be assessed using claims-based data and 10 were at risk for misclassification due to coding error. 25 This finding indicates the importance of Health IT platforms and the application of novel techniques to implement and measure PHM strategies.
Natural language processing (NLP) 53, 54 has been used successfully to develop clinical decision support tools for colonoscopy surveillance intervals and monitoring of provider performance (i.e. adenoma detection rate), [55] [56] [57] [58] [59] [60] as well as to identify patients with cirrhosis who would benefit from preventive services (i.e. hepatocellular carcinoma screening). 61 Although early work in IBD involved the use NLP for patient identification, 62 phenotype classification, 63 and for differentiating surveillance from non-surveillance colonoscopies, 64 the application of NLP for performance measurement and tracking is still in its infancy. Furthermore, there are still concerns and barriers related to the tradeoffs between individual and institutional privacy and the societal benefits of sharing clinical data, and to the practical challenges of harmonizing data across several institutions to build predictive models and decision support systems.
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Strategies for Resource-limited Settings
With increasing global incidence and prevalence of IBD, particularly in newly industrialized nations, the burden of IBD will continually rise. As our knowledge on the epidemiology and natural history of IBD in these countries builds, resource-adaptive and culturally sensitive PHM strategies would be warranted. With limited access to specialists, let alone IBD specialists in these regions, provider education through development of regional clinical guidelines and clinical decision support tools, development of timely referral and access mechanisms through integrated care, remote monitoring strategies, as well as development of patient selfmanagement and well-informed widespread community resources, would be important. The use of expensive biologic medications may be cost prohibitive, and engaging national governments to inform optimal health policies would be critical. At the same time, a careful and systematic assessment of risks-benefit and cost effectiveness of interventions, such as treat to target, etc.
would be warranted. For example, although intensive and repeated endoscopic monitoring for CD may not be feasible, use of stool-based biomarkers may be a reasonable alternative.
FUTURE DIRECTIONS
Significant progress has been made in improving the quality of care delivered to IBD patients, but gaps remain. Beside systematic and accurate risk stratification strategies, or implementation M A N U S C R I P T
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of innovative care delivery models and ongoing monitoring of key quality metrics, factors that merit prospective evaluation in promoting PHM include integration of IT and clinical information systems with omics' and precision medicine to build tools that identify and predict provider trends in healthcare delivery and treatment. It will also be important to evaluate trends in healthcare use and adherence, determine risk of disease progression for individual patients, and predict response to therapy. These factors could help patients avoid ineffective therapies, which increase the likelihood of poor outcomes (i.e. surgery), [71] [72] [73] identify patients most likely to benefit from highly effective therapeutic interventions early in the disease course, [74] [75] [76] [77] and created personalized decision support tools for patients at risk for high healthcare utilization and providers at risk for variability in care. 78 We have outlined the essential components of an effective PHM strategy and actionable items for healthcare systems to consider when implementing these strategies for IBD patients.
Consideration will need to be given on the individualization of PHM strategy aspects to local needs and resources, and the integration of information technology platforms. 
